4 completed, 3 not yet recruiting. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Not yet recruiting 3 |
| Phase 1 | 3 | Not yet recruiting 2, Completed 1 |
Follow BioLite, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients PDC-1421 Capsule - Major Depressive Disorder | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 12 | 2027-01-15 | 2026-04-20 |
| A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) BLEX 404 Oral Liquid - Myelodysplastic Syndrome (MDS) | Phase 2 | Not yet recruiting | BioLite, Inc. | 52 | 2027-01-01 | 2026-04-13 |
| Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. BLEX 404 Oral Liquid - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 44 | 2027-01-01 | 2026-04-13 |
| PDC-1421 Treatment in Adult Patients With ADHD PDC-1421 Capsule, Placebo - Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Completed | BioLite, Inc. | 99 | 2022-04-07 | 2026-05-06 |
| A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD) PDC-1421 Capsule - Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Completed | BioLite, Inc. | 6 | 2019-12-01 | 2021-12-01 |
| A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder PDC-1421 Capsule, placebo - Major Depressive Disorder | Phase 2 | Completed | BioLite, Inc. | 72 | 2015-04-10 | 2021-07-22 |
| A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression PDC-1421, Placebo - Major Depressive Disorder | Phase 1 | Completed | BioLite, Inc. | 30 | 2012-11-01 | 2020-08-13 |
Depressive Disorder, Major (3) · Attention Deficit Disorder with Hyperactivity (2) · Breast Neoplasms (1) · Depression (1) · Myelodysplastic Syndromes (1) · Triple Negative Breast Neoplasms (1)
Starch (1)
United States (4) · Taiwan (3)
Richard King, Ph.D. (2) · Cheng-Ta Li, MD (1) · Hsien-Ming Wu, M.S. (1) · Keith R McBurnett, PhD (1) · Tung-Ping Su, M.D (1)